title: Intravenous lidocaine infusion facilitates acute rehabilitation after laparoscopic colectomy.
abstract: BACKGROUND
  Intravenous infusion of lidocaine decreases postoperative pain and speeds the return of bowel function. The authors therefore tested the hypothesis that perioperative lidocaine infusion facilitates acute rehabilitation protocol in patients undergoing laparoscopic colectomy.
  
  
  METHODS
  Forty patients scheduled to undergo laparoscopic colectomy were randomly allocated to receive intravenous lidocaine (bolus injection of 1.5 mg/kg lidocaine at induction of anesthesia, then a continuous infusion of 2 mg.kg.h intraoperatively and 1.33 mg.kg.h for 24 h postoperatively) or an equal volume of saline. All patients received similar intensive postoperative rehabilitation. Postoperative pain scores, opioid consumption, and fatigue scores were measured. Times to first flatus, defecation, and hospital discharge were recorded. Postoperative endocrine (cortisol and catecholamines) and metabolic (leukocytes, C-reactive protein, and glucose) responses were measured for 48 h. Data (presented as median [25-75% interquartile range], lidocaine vs. saline groups) were analyzed using Mann-Whitney tests. P<0.05 was considered statistically significant.
  
  
  RESULTS
  Patient demographics were similar in the two groups. Times to first flatus (17 [11-24] vs. 28 [25-33] h; P<0.001), defecation (28 [24-37] vs. 51 [41-70] h; P=0.001), and hospital discharge (2 [2-3] vs. 3 [3-4] days; P=0.001) were significantly shorter in patients who received lidocaine. Lidocaine significantly reduced opioid consumption (8 [5-18] vs. 22 [14-36] mg; P=0.005) and postoperative pain and fatigue scores. In contrast, endocrine and metabolic responses were similar in the two groups.
  
  
  CONCLUSIONS
  Intravenous lidocaine improves postoperative analgesia, fatigue, and bowel function after laparoscopic colectomy. These benefits are associated with a significant reduction in hospital stay.
authors.affiliation: Department of Anesthesia and Intensive Care Medicine, Centre Hospitalier Universitaire (CHU) de Liège, University of Liège, Belgium.
authors.forename: Abdourahamane
authors.initials: A
authors.lastname: Kaba
authors.forename: Stanislas R
authors.initials: SR
authors.lastname: Laurent
authors.forename: Bernard J
authors.initials: BJ
authors.lastname: Detroz
authors.forename: Daniel I
authors.initials: DI
authors.lastname: Sessler
authors.forename: Marcel E
authors.initials: ME
authors.lastname: Durieux
authors.forename: Maurice L
authors.initials: ML
authors.lastname: Lamy
authors.forename: Jean L
authors.initials: JL
authors.lastname: Joris
mesh_terms: D000328:Adult; D000368:Aged; D000779:Anesthetics, Local / Q000008:administration & dosage*; D003082:Colectomy / Q000009:adverse effects / Q000534:rehabilitation*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D010535:Laparoscopy / Q000009:adverse effects; D008012:Lidocaine / Q000008:administration & dosage*; D008297:Male; D008738:Methyl Ethers / Q000008:administration & dosage; D008875:Middle Aged; D010149:Postoperative Pain / Q000188:drug therapy*; D010892:Pirinitramide / Q000008:administration & dosage; D011183:Postoperative Complications / Q000517:prevention & control; D000077149:Sevoflurane; D017409:Sufentanil / Q000008:administration & dosage
chemical_list: D000779:Anesthetics, Local; D008738:Methyl Ethers; D000077149:Sevoflurane; D010892:Pirinitramide; D008012:Lidocaine; D017409:Sufentanil